Canaccord lowered the firm’s price target on Quipt Home Medical to $9 from $11 and keeps a Buy rating on the shares. The firm said Quipt’s business continued to perform in 4Q as bad debt improved and margins continued to rise. With a favorable reimbursement and regulatory environment, strong sleep demand trends, and an increased salesforce to drive organic growth, Canaccord is optimistic that 20’24 is starting off on the right foot.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on QIPT:
- Quipt Home Medical Reports Record Fourth Quarter and Fiscal Year 2023 Financial Results Posting Revenue Growth of 59% and Adjusted EBITDA Growth of 73%
- Quipt Home Medical reports Q4 EPS (3c), consensus 0c
- Options Volatility and Implied Earnings Moves Today, December 18, 2023
- Options Volatility and Implied Earnings Moves This Week, December 18 – December 21, 2023
- Quipt Home Medical Corp (QIPT) Q4 Earnings Cheat Sheet
